IRS Correspondence Audit Operational Updates Compliance Guidance and Systemic Reforms Xenon Pharmaceuticals XENE Unveils Robust Azetukalner Phase III Data Q3 NDA Filing Plans at Bloom Burton Conference Is Patria PAX stock breaking out Q4 2025 Profit Surprises